Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

Aripiprazole to Reduce Cocaine Relapse

Phase 1
Completed
Conditions
Cocaine-Related Disorders
Interventions
Drug: Placebos
Drug: Aripiprazole
First Posted Date
2006-01-13
Last Posted Date
2017-04-06
Lead Sponsor
Craig Rush
Target Recruit Count
41
Registration Number
NCT00276874
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

Study of Aripiprazole in Patients With Bipolar I Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-11-24
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
400
Registration Number
NCT00257972
Locations
🇬🇧

Local Institution, Surbiton, Middlesex, United Kingdom

Trial of Aripiprazole in the Treatment of CD in Adolescents

Phase 4
Completed
Conditions
Conduct Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2005-11-08
Last Posted Date
2017-07-11
Lead Sponsor
University of Iowa
Target Recruit Count
12
Registration Number
NCT00250705
Locations
🇺🇸

The University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Side Effects of Newer Antipsychotics in Older Adults

First Posted Date
2005-10-27
Last Posted Date
2018-12-17
Lead Sponsor
Veterans Medical Research Foundation
Target Recruit Count
406
Registration Number
NCT00245206
Locations
🇺🇸

University of California, San Diego, San Diego, California, United States

Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 4
Completed
Conditions
Tic Disorders
Tourette's Syndrome
Interventions
Drug: Aripiprazole
First Posted Date
2005-10-18
Last Posted Date
2016-12-09
Lead Sponsor
NYU Langone Health
Target Recruit Count
11
Registration Number
NCT00241176
Locations
🇺🇸

NYU Child Study Center, New York, New York, United States

Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
First Posted Date
2005-10-17
Last Posted Date
2014-12-19
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
119
Registration Number
NCT00239356
Locations
🇬🇧

Local Institution, Antrim, United Kingdom

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-10-13
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
1200
Registration Number
NCT00237939
Locations
🇪🇸

Local Institution, Sevilla, Spain

Schizophrenia Trial of Aripiprazole

First Posted Date
2005-10-13
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
700
Registration Number
NCT00237913
Locations
🇬🇧

Local Institution, Birmingham, West Midlands, United Kingdom

Aripiprazole Treatment of Prodromal Patients

Phase 2
Completed
Conditions
Schizophrenia
Psychosis
First Posted Date
2005-10-12
Last Posted Date
2014-06-06
Lead Sponsor
Yale University
Target Recruit Count
15
Registration Number
NCT00237874
Locations
🇺🇸

Institute of Living, Hartford, Connecticut, United States

🇺🇸

Yale School of Medicine, New Haven, Connecticut, United States

A Switch Study of BMS-337039 in Schizophrenic Out-patients

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
First Posted Date
2005-10-05
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
450
Registration Number
NCT00232687
Locations
🇬🇧

Local Institution, Haywards Health, West Sussex, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy